UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 26, 2011
ROCKWELL MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Michigan
|
|
000-23661
|
|
38-3317208 |
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
30142 Wixom Road,Wixom, Michigan 48393
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code (248) 960-9009
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Explanatory Note:
This Form 8-K/A is being filed as an amendment to the Current Report on Form 8-K filed by
Rockwell Medical Technologies, Inc. (the Company) on June 1, 2011 (the Original Filing). The
purpose of this amendment is to disclose the Companys decision regarding how frequently it will
conduct future shareholder advisory votes on the compensation of its named executive officers. Item
5.07 of the Original Filing is amended and restated as set forth below. There are no other changes
to the Original Filing.
|
|
|
Item 5.07 |
|
Submission of Matters to a Vote of Security Holders. |
At the Companys Annual Meeting of Shareholders on May 26, 2011, the shareholders voted to (1)
reelect one incumbent director for a term expiring in 2014, (2) recommend, by non-binding vote,
support for the compensation of the Companys named executive officers, (3) recommend, by
non-binding vote, that the frequency of shareholder advisory votes on the compensation of the
Companys named executive officers be every three years, (4) approve the amendment and restatement
of the LTIP including reapproval of the performance measures in the LTIP for purposes of the
performance based compensation exemption in Section 162(m) of the Internal Revenue Code, and (5)
ratify the selection of Plante & Moran, PLLC as the Companys independent registered public
accounting firm for 2011. The following tables set forth the final voting results on each matter.
|
|
|
|
|
|
|
|
|
|
|
|
|
Director Nominee |
|
For |
|
Withheld |
|
Broker Non-Votes |
Kenneth L. Holt |
|
|
7,574,460 |
|
|
|
132,647 |
|
|
|
9,291,918 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposal |
|
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
Non-binding
advisory vote on
compensation of
named executive
officers |
|
|
7,096,602 |
|
|
|
359,560 |
|
|
|
250,945 |
|
|
|
9,291,918 |
|
Approve amendment
and restatement of
LTIP and reapproval
of performance
measures |
|
|
6,469,251 |
|
|
|
1,031,350 |
|
|
|
206,506 |
|
|
|
9,291,918 |
|
Ratify the
selection of Plante
& Moran, PLLC |
|
|
16,784,114 |
|
|
|
114,759 |
|
|
|
100,152 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposal |
|
1 Year |
|
2 Year |
|
3 Year |
|
Abstain |
|
Broker Non-Votes |
Non-binding
advisory vote on
frequency of
shareholder votes
on the compensation
of named executive
officers |
|
|
1,805,324 |
|
|
|
320,556 |
|
|
|
5,300,844 |
|
|
|
280,383 |
|
|
|
9,291,918 |
|
After considering the results of the shareholder advisory vote on executive compensation and
other factors, including the Boards recommendation to the shareholders, the Companys Board of
Directors determined that it will hold a triennial advisory vote on the compensation of the
Companys named executive officers until the next vote on the frequency of such advisory vote is
conducted, which will be no later than the 2017 annual shareholders meeting, or until the Board of
Directors determines that a different frequency for such advisory vote would be in the best
interest of the Companys shareholders.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
ROCKWELL MEDICAL TECHNOLOGIES, INC.
|
|
Date: October 5, 2011 |
By: |
/s/ Thomas E. Klema
|
|
|
|
Thomas E. Klema |
|
|
|
Its: Chief Financial Officer |
|
|